Hemorrhage Treatment Report of Patients Suffering from Glanzmann’s Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children’s Hospital
Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 3
Abstract
Background: The present study evaluated treatment outcomes and the treatment indexes among Glanzmann’s patients in Mofid Children’s Hospital, Tehran, Iran. Patients and Methods: A retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 Glanzmann’s patients with bleeding therapeutic records in Mofid Children’s Hospital, Tehran, Iran, from 2006 to 2011. Results: The total recombinant factor VIIa used was 137mg and the total infused platelet concentrates was 68 units, with platelets used in order being: apheresis platelets, leukoreduced pooled platelets, leukoreduced platelets, and random donor platelets with 35, 16, 13 and 4 units respectively. In 90% of bleeding sequences, leukoreduced platelets were available and the average admission per patient was 3.46 times, the average leukoreduced platelets consumption per patient was 4.26 units and the average use of recombinant factor VIIa per patient was 9.13mg. Other Indexes included the average hospitalization per patient per year of 0.69% times, the average consumption of non- random platelet per patient per year of 0.85% units, the average consumption of recombinant factor VIIa per patient per year of 1.83mg, the average consumption of non random platelet for any hemorrhage incidence or elective surgery of 1.3 units, and the average consumption of recombinant factor VIIa for any hemorrhage incidence of 2.8mg. Conclusion: By extracting the consumption of therapeutical products to treat Glanzmann’s thrombasthenia in our center we could estimate the future treatment needs of our medical center. More thorough investigation of patients from different age groups is recommended to achieve more reliable results. Key Words: Glanzmann’s thrombasthenia, platelet, rFVIIa, treatment index.
Authors and Affiliations
Peyman Eshghi, Alireza Jenabzadeh, Behnaz Habibpanah
Keywords
Related Articles
- EP ID EP364642
- DOI -
- Views 67
- Downloads 0
ABO blood groups and prognosis of breast cancer: a case-control study in Arak/Iran
Background: To explore a possible rela!onship among blood groups and the prognosis of breast cancer, this case- control study was carried out in Arak city, Arak province, Iran. Materials and Methods: One hundred and thir...
FMS-like Tyrosine Kinase-3 Mutation in a Child with Standard-risk ALL and Normal Karyotype
FMS-like tyrosine kinase-3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. Mutations of FMS-like tyrosine kinase-3...
Heterozygote Hemoglobin J Iran in Combination with Hemoglobin H Disease
This is a report concerning a concurrent case of hemoglobin J Iran (Hb J Iran) and Hemoglobin H (Hb H) disease in an Iranian woman. The patient was coincidentally found during the course of routine pre-marital genetic co...
Association between Red Cell Distribution Width and Mortality in Pediatric Patients Admitted to Intensive Care Units
Background: Red cell distribution width (RDW) is a routine laboratory measure that could be used as a predictor of mortality in critically ill patients. Identification of patients at risk for mortality early in the cours...
Mucinous and Non-Mucinous Adenocarcinoma in Colorectal Cancer Patients
Background: The oncologic behavior of mucinous adenocarcinoma (MA) of colorectal differs from non-mucinous adenocarcinoma (NMA). MA is more advanced at diagnosis and has a poorer prognosis than NMA. We aimed to evaluate...